Subtopic Deep Dive
p53 Mutations in Cancer
Research Guide
What is p53 Mutations in Cancer?
p53 mutations in cancer refer to genetic alterations in the TP53 tumor suppressor gene that inactivate its DNA damage response function, often through dominant-negative or gain-of-function hotspot mutations prevalent in over 50% of human tumors.
These mutations disrupt p53's role in apoptosis, cell cycle arrest, and genome stability, leading to uncontrolled proliferation (Hanahan and Weinberg, 2000). Hotspot mutations like R175H and R248Q exhibit tissue-specific patterns and prognostic impacts across cancers. Over 100 studies document p53 mutation spectra in tumor types including glioma and hepatocellular carcinoma.
Why It Matters
p53 mutations drive tumor progression and therapy resistance, as seen in gliomas where they correlate with aggressive invasion (Maher et al., 2001). In hepatocellular carcinoma, p53 alterations serve as biomarkers for poor prognosis and targeted therapies (Zucman-Rossi et al., 2015). Understanding gain-of-function effects enables personalized diagnostics, with apoptosis pathway insights from p53 defects informing TRAIL-based treatments (Ashkenazi et al., 1999). Drug resistance mechanisms linked to p53 loss highlight needs for kinase-targeted interventions (Longley and Johnston, 2005).
Key Research Challenges
Classifying Mutation Effects
Distinguishing loss-of-function from dominant-negative or gain-of-function p53 mutations requires functional assays beyond sequencing. Hotspot mutations like R248Q show context-dependent oncogenicity (Maher et al., 2001). Over 50% of cancers carry ambiguous p53 variants needing standardized classification.
Tissue-Specific Patterns
p53 mutation spectra vary by cancer type, such as G-to-A transitions in liver tumors versus UV-signature mutations in skin cancers (Zucman-Rossi et al., 2015). Prognostic impacts differ across tissues, complicating universal models. Hanahan and Weinberg (2000) note pathway context influences mutation selection.
Therapy Resistance Links
Mutant p53 promotes chemoresistance via altered apoptosis signaling (Wong, 2011). Longley and Johnston (2005) describe acquired resistance in p53-deficient tumors. Targeting gain-of-function requires overcoming pathway redundancies like PI3K/Akt (He et al., 2021).
Essential Papers
The Hallmarks of Cancer
Douglas Hanahan, Robert A. Weinberg · 2000 · Cell · 28.3K citations
Apoptosis in cancer: from pathogenesis to treatment
Rebecca Shin-Yee Wong · 2011 · Journal of Experimental & Clinical Cancer Research · 2.8K citations
Apoptosis is an ordered and orchestrated cellular process that occurs in physiological and pathological conditions. It is also one of the most studied topics among cell biologists. An understanding...
Safety and antitumor activity of recombinant soluble Apo2 ligand
Avi Ashkenazi, Roger Pai, Sharon Fong et al. · 1999 · Journal of Clinical Investigation · 2.2K citations
TNF and Fas ligand induce apoptosis in tumor cells; however, their severe toxicity toward normal tissues hampers their application to cancer therapy. Apo2 ligand (Apo2L, or TRAIL) is a related mole...
Risk Factors and Preventions of Breast Cancer
Yi-Sheng Sun, Zhao Zhao, Zhang-Nv Yang et al. · 2017 · International Journal of Biological Sciences · 1.9K citations
Breast cancer is the second leading cause of cancer deaths among women. The development of breast cancer is a multi-step process involving multiple cell types, and its prevention remains challengin...
Molecular mechanisms of drug resistance
DB Longley, PG Johnston · 2005 · The Journal of Pathology · 1.6K citations
Abstract Resistance to chemotherapy limits the effectiveness of anti‐cancer drug treatment. Tumours may be intrinsically drug‐resistant or develop resistance to chemotherapy during treatment. Acqui...
Targeting PI3K/Akt signal transduction for cancer therapy
Yan He, Miao Sun, Guo Geng Zhang et al. · 2021 · Signal Transduction and Targeted Therapy · 1.6K citations
The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy (Review)
Fatima Ardito, Michele Giuliani, D. Perrone et al. · 2017 · International Journal of Molecular Medicine · 1.3K citations
Protein phosphorylation is an impo-rtant cellular regulatory mechanism as many enzymes and receptors are activated/deactivated by phosphorylation and dephosphorylation events, by means of kinases a...
Reading Guide
Foundational Papers
Start with Hanahan and Weinberg (2000) for p53 in cancer hallmarks (28274 citations), then Wong (2011) for apoptosis roles, and Maher et al. (2001) for mutation genetics in gliomas.
Recent Advances
Study Zucman-Rossi et al. (2015) for HCC p53 biomarkers and He et al. (2021) for PI3K/p53 therapy links.
Core Methods
Core techniques include hotspot sequencing, dominant-negative assays, gain-of-function modeling, and pathway analysis via apoptosis inducers like TRAIL (Ashkenazi et al., 1999).
How PapersFlow Helps You Research p53 Mutations in Cancer
Discover & Search
Research Agent uses searchPapers and exaSearch to retrieve p53 mutation literature from 250M+ OpenAlex papers, then citationGraph maps connections from Hanahan and Weinberg (2000) to recent works like Zucman-Rossi et al. (2015). findSimilarPapers expands to tissue-specific spectra from Maher et al. (2001).
Analyze & Verify
Analysis Agent employs readPaperContent on Maher et al. (2001) for glioma p53 details, verifyResponse with CoVe to check mutation claims against abstracts, and runPythonAnalysis for statistical verification of mutation frequencies using pandas on extracted data. GRADE grading scores evidence strength for prognostic claims.
Synthesize & Write
Synthesis Agent detects gaps in p53 gain-of-function therapies via contradiction flagging across Wong (2011) and Longley (2005), while Writing Agent uses latexEditText, latexSyncCitations for Hanahan (2000), and latexCompile for reports. exportMermaid visualizes p53 pathway diagrams with mutation nodes.
Use Cases
"Analyze p53 mutation frequencies in glioma vs HCC datasets."
Research Agent → searchPapers('p53 mutations glioma HCC') → Analysis Agent → runPythonAnalysis(pandas frequency stats on Maher 2001 + Zucman-Rossi 2015 data) → matplotlib plot of tissue-specific spectra.
"Draft LaTeX review on p53 dominant-negative effects."
Synthesis Agent → gap detection in Hanahan 2000 + Wong 2011 → Writing Agent → latexEditText(structure sections) → latexSyncCitations(10 papers) → latexCompile(PDF with p53 pathway figure).
"Find code for p53 mutation classification models."
Research Agent → paperExtractUrls(recent p53 papers) → paperFindGithubRepo → githubRepoInspect(pull mutation classifier scripts) → runPythonAnalysis(test on hotspot data from abstracts).
Automated Workflows
Deep Research workflow conducts systematic review of 50+ p53 papers: searchPapers → citationGraph → GRADE all claims → structured report on mutation spectra. DeepScan applies 7-step analysis with CoVe checkpoints to verify gain-of-function evidence from Ashkenazi (1999) to He (2021). Theorizer generates hypotheses on p53-PI3K crosstalk from Longley (2005) and pathway integrations.
Frequently Asked Questions
What defines p53 mutations in cancer?
p53 mutations are TP53 gene alterations causing loss of tumor suppression via dominant-negative or gain-of-function at hotspots like R175H, occurring in >50% of cancers (Hanahan and Weinberg, 2000).
What methods study p53 mutation effects?
Functional assays distinguish dominant-negative from gain-of-function, with sequencing for spectra and apoptosis models for impacts (Wong, 2011; Maher et al., 2001).
What are key papers on p53 mutations?
Hanahan and Weinberg (2000, 28274 citations) outline hallmarks including p53 loss; Maher et al. (2001) details glioma genetics; Zucman-Rossi et al. (2015) covers HCC biomarkers.
What open problems exist in p53 research?
Challenges include tissue-specific prognostic models, targeting gain-of-function without toxicity, and linking to drug resistance (Longley and Johnston, 2005; He et al., 2021).
Research Cancer-related Molecular Pathways with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching p53 Mutations in Cancer with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Cancer-related Molecular Pathways Research Guide